Companies › Tenax Therapeutics
1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Levosimendan (TNX-103) Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator | PDE3A, PDE3B, TNNC1, TNNI3, TNNT2 | Phase 3 | Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic Shock | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04020263 | Levosimendan (TNX-103) | Phase 3 | Cardiogenic Shock | Cardiovascular | Feb 2027 |
| NCT07105202 | Levosimendan (TNX-103) | Phase 4 | Mechanical Ventilation | Other | Aug 2027 |
| NCT07288398 | Levosimendan (TNX-103) | Phase 3 | Pulmonary Hypertension Associated With HFpEF | Cardiovascular | Jun 2028 |
| NCT05983250 | Levosimendan (TNX-103) | Phase 3 | Pulmonary Hypertension | Cardiovascular | Oct 2028 |
Cash of $114m on 2026-09-30; operating cash outflow about $48m a year; runway about 28 months at that burn, to Feb 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
MediciNova Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Merck & Co. (MSD)
Braveheart Bio RHEACELL GmbH & Co. KG Mezzion Pharma Getz Pharma Tetra Discovery Partners
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.